Thyrotropin alfa

Drug Profile

Thyrotropin alfa

Alternative Names: MRrhTSH; Recombinant human thyroid stimulating hormone; rhTSH; rhTSH-M; Thyrogen; Thyrotrophin alpha; Thyrotropin; Thyrotropin alpha for injection

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Genzyme Corporation; Odense University Hospital; Sanofi Genzyme
  • Class Diagnostic agents; Pituitary gonadotropins
  • Mechanism of Action Thyrotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thyroid cancer
  • Discontinued Goitre

Most Recent Events

  • 13 May 2015 Discontinued - Phase-II for Goitre in Brazil, Canada, Denmark, France, Germany, Italy and Netherlands (IM, controlled-release)
  • 13 May 2015 Discontinued - Phase-II for Goitre in Denmark (IM, immediate-release)
  • 13 May 2015 Discontinued - Phase-III for Goitre in USA (IM, controlled-release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top